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Abstract
Purpose The aim of this study was to determine if the
measurement of blood biomarkers of glucose cerebral
metabolism, performed with retrograde jugular catheter,
could predict the outcome of poor-grade aneurysmal sub-
arachnoid hemorrhage (aSAH) patients.
Methods This study was conducted in 68 poor-grade
aSAH patients. A total of 4,024 blood samples obtained
from jugular and radial catheters were analyzed for glu-
cose, lactate, and oxygen content every 8 h for
10 ± 0.5 days. Metabolic ratio (MR) and lactate–oxygen
index (LOI) were obtained by ratios using arterio-jugular
differences. Functional outcome was evaluated at
12 months with the Glasgow Outcome Scale.
Results Outcome was unfavorable in 40 patients. In this
group of patients, the MR was significantly lower
(p < 0.0001) and the LOI was significantly higher
(p = 0.0001) than in the group with favorable outcome.
The MR cutoff value, below which the patients are likely to
have an unfavorable outcome, was determined to be 3.35.
More interestingly, the data obtained in this study dem-
onstrated that the patients achieving an unfavorable
outcome were distinguished from those with a favorable
outcome by having at least three events of MR inferior to
3.35 (sensitivity = 90 %, specificity = 82.1 %). More-
over, in patients who developed cerebral vasospasm, we
observed a significant decrease in the MR.
Conclusion Our data provide additional support to the
view that the MR is a reliable marker for predicting the
outcome of poor-grade aSAH patients. Prospective stud-
ies are needed to confirm its value in multimodal
monitoring.
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Introduction
Despite advances in the monitoring of patients with
aneurysmal subarachnoid hemorrhage (aSAH), mortality
remains high. About 46 % of the survivors develop cog-
nitive and functional disorders and 25 % develop severe
disability [1, 2]. In poor-grade aSAH patients (18–24 %
approximately), the severity of bleeding, the development
of global cerebral edema, acute ischemic injury, and
vasospasm are pathological changes that determine a
worse long-term functional outcome [3–5]. After brain
injury, secondary pathological events involving the exci-
totoxic pathway and impairment of cerebral oxidative
metabolism are likely to influence the outcome of the
patients. Neuromonitoring is crucial for poor-grade aSAH
patients in whom the neurological examination becomes
limited. Brain metabolism monitoring in conjunction with
cerebral dynamic parameters monitoring could help detect
secondary brain insults that are still potentially reversible
in routine clinical practice and could improve the long-
term functional outcome. In addition to intracranial
pressure (ICP) and cerebral perfusion pressure (CPP)
measurement, several of different brain monitoring
methods is currently available, including jugular venous
catheterization, brain parenchymal oxygenation, positron
emission tomography, and brain microdialysis [6–8].
Neuromonitoring was proposed to optimize treatment and
improve long-term outcome [5, 9]. Secondary pathologi-
cal events involving the excitotoxic pathway and
impairment of cerebral oxidative metabolism are linked to
the outcome of the patients. Glycolysis and lactate
metabolism can affect neurological function recovery
[10]. In 2006, using arterio-jugular differences in glucose
and oxygen content, relative hyperglycolysis (RH) was
reported to be associated with poor outcome in aSAH
[11]. To our knowledge, these preliminary data were
never reported again in others cohorts of SAH patients,
leading us to question the utility of this monitoring in
clinical routine.
The present observational study was therefore under-
taken to revisit the utility of the biochemical ratios
calculated from the measurements of oxygen, lactate, and
glucose in jugular and arterial blood in a cohort of 68
aSAH patients with poor-grade clinical status.
Methods
Study Design and Patient Population
This observational study included 68 poor-grade aSAH
patients who had been admitted to the Neurocritical Care
Unit of the Neurological Hospital (Lyon University Hospital,
France). It received local ethics committee approval. On
admission, the patient’s clinical severity status was assessed
according to the World Federation of Neurosurgical Socie-
ties (WFNS) scale [12]. Computed tomography (CT) scan
was used to confirm the subarachnoid hemorrhage and to
evaluate clot thickness. CT scan findings were categorized
using Fisher’s scale [13]. The presence of an aneurysm was
confirmed by cerebral angiography and aneurysms were
treated within 48 h after admission by endovascular coiling
or surgical clipping. Acute hydrocephalus was treated with
immediate placement of a ventricular drain. Patients with a
nonaneurysmal SAH, with a good clinical status (WFNS
grades 1–3) and survivors without 12-month outcome
assessment were excluded from this study.
Clinical Management
All patients were managed in the neurological intensive
care unit following the standard guidelines for the man-
agement of SAH [14, 15]. Intubation, mechanical
ventilation, and sedation with fentanyl associated to pro-
pofol, or midazolam were performed when required. All
patients underwent multimodal monitoring. Management
aimed to maintain the ICP below 20 mmHg and the CPP
(CPP = MABP - ICP) above 70 mmHg by adjusting the
mean arterial blood pressure (MABP). Cardiopulmonary
functions were screened, body temperature was monitored,
and normovolemia was maintained. Arterial blood glucose
levels were targeted to be within a range of 4.0–8.0 mmol/
L. In order to detect any onset of cerebral vasospasm, a
transcranial Doppler was performed daily. Cerebral vaso-
spasm was confirmed by angiography and treated by triple
H-therapy and/or by angioplasty or intracranial artery
nimodipine infusion. Since this study was observational,
MR result values were not taken into account and conse-
quently, did not influence patient management.
Jugular Bulb Catheterization
Jugular catheterization was performed within 48 h of onset
and maintained in survivors for 10 ± 0.5 days (mean ±
SEM). The catheter was inserted into the jugular vein
ipsilateral to the aSAH in a retrograde way toward the skull
base until a resistance was felt. Then, it was moved about
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1 cm backwards. When the aneurysm was located on the
anterior communicating artery, the catheter was inserted on
the side of the more injured cerebral hemisphere. Correct
position of the catheter in the jugular bulb was checked by
lateral neck X-ray. Blood withdrawal was scheduled every
8 h.
Blood Sampling and Analysis for pH, PaCO2, Glucose,
Lactate, and Oxygen Content
The jugular and arterial blood samples were collected in
two syringes with lithium-heparin. Analysis was immedi-
ately performed on a blood gas analyzer (ABL system,
Radiometer, Copenhagen, Denmark). Oxygen content,
lactate, and glucose levels (expressed in mmol/L) and
jugular venous oxygen saturation (SjVO2) were measured.
Arterio-venous differences for oxygen (avDO2) and glu-
cose (avDgluc) and jugular venous arterial differences for
lactate (JaDL) were calculated. The lactate–oxygen index
(LOI) was calculated as the ratio [JaDL (mmol/L)]/[avDO2
(mmol/L)]. The metabolic ratio (MR), which provides an
assessment of the cerebral metabolic status, was defined as
the ratio [avDO2 (mmol/L)]/[avDgluc (mmol/L)] [11].
Normal values for JaDL and LOI were obtained from
reference study by Gibbs et al. [16]. In this text, a bio-
chemical event was defined as a complete set of raw data
obtained from a blood sampling including both an arterial
and a jugular venous sample.
Outcome Measurement
Neurological outcome was evaluated 12 months after the
aSAH using the Glasgow Outcome Scale (GOS) [17].
Data Processing and Statistical Analysis
Patients were assigned either to the unfavorable outcome
group (GOS 1–3) or the favorable outcome group (GOS
4–5). They were also assigned either to the non-survivors
group (GOS 1) or the survivors group (GOS 2–5). We first
compared the global mean and median of biomarkers in
these different outcome populations. Based on these
results, we secondly determined for each patient, the mean
of the 25 % lowest MR values (defined as MR min) and the
mean of the 25 % highest LOI values (defined as LOI max)
during follow-up. Then, we compared the MR min and the
LOI max in the unfavorable and favorable outcome groups.
Moreover, we determined the cutoff values using a ROC
curve analysis able to discriminate between unfavorable
and favorable outcome groups. Note that for SjVO2, we
used the minimal SjVO2 (using the lowest values) and the
maximal SjVO2 (using the highest values) obtained in the
two different outcome groups.
Once the cutoff was determined for each biochemical
marker, we used a ROC curve analysis to assess the
prognostic utility of the number of events which are below
or above the cutoff, depending on the biomarker studied.
Statistical Analyses Were Performed to Compare Groups
of Patients
Analysis of variance was used for age, a 2 9 2 contingency
analysis (Chi square test for sex ratios, WFNS grade, and
treatment of aneurysm), a Fisher’s exact test for aneurysm
location and a Mann–Whitney non-parametric U test or
Student’s t test for blood biomarkers. Biomarker accuracy
to predict outcome was characterized using a ROC analysis
to determine the cutoff values. Multiple regression with
backward selection was used to test the association
between the different parameters evaluated (age, WFNS,
LOI, SjVO2, and MR) and outcome. The Friedman test was
used to compare the changes in MR values during cerebral
vasospasm. Results were expressed either as mean ±
standard deviation or as median (25th–75th percentiles).
Differences were considered statistically significant at p <
0.05. Statistical analyses used MedCalc version 11.3.1.0
(http://www.medcalc.be).
Results
Description of the Population
A total of 68 patients were investigated (27 males, 41
females) with a mean age of 50 years (range 18–75 years).
Endovascular coiling and surgical clipping were performed
to treat aneurysms in 82.4 and 17.6 % of the patients,
respectively. Demographic data are summarized in Table 1.
The patients were monitored for a mean period of 10 days.
At 12 months post-SAH, the mortality rate was 38.2 %.
Overall, outcome was unfavorable in the majority of patients
(59 %). No significant difference was found regarding age,
sex, WFNS score, and treatment, between the patients with
unfavorable (GOS 1–3) and those with favorable (GOS 4–5)
outcome, a result which allows an unbiased comparison
between the two groups of aSAH patients.
Raw Data in the Population
A total of 2,012 complete biochemical events were inves-
tigated (corresponding to 4,024 samples). Using the
averaged values from each patient, the MR and LOI values
were found significantly lower and higher, respectively, in
the unfavorable group than those in the favorable outcome
(p = 0.0001 and p < 0.0001, respectively) (Table 2). For
arterial lactate, jugular venous lactate, JaDL, SjVO2, and
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avDO2, a statistically significant difference was found
between the unfavorable and favorable outcome groups
(Table 2).
Designing Cutoffs
Table 3 shows the mean of the 25 % lowest values for MR
(MR min) and minimal SjVO2 (SjVO2 min) and the mean
of the 25 % highest values for LOI (LOI max) and maxi-
mal SjVO2 (SjVO2 max). The ROC curves were generated
from these values. We determined the cutoff values which
reached the best area under the curve (AUC) for the LOI
and MR (0.08 and 3.35, respectively; Table 3). We were
unable to find any cutoff value for SjVO2. For further
studies concerning the prediction of the outcome, we
decided to set the cutoff at 55 and 75 %, respectively.
Table 1 Demographic and clinical data
Population for 12 months prognosis (n = 68)
Non-survivors
(n = 26)
Survivors
(n = 42)
p value Unfavorable outcome
(GOS 1–3) (n = 40)
Favorable outcome
(GOS 4–5) (n = 28)
p value
Age (yrs), mean ± SD (range) 48.4 ± 9.5 (25–59) 50.8 + 12.4 (18–75) 0.39 48.8 ± 10.3 (25–70) 51.4 + 12.8 (18–75) 0.36
Gender, male/female 9/17 18/24 0.68 15/25 12/16 0.85
WFNS grade
IV 6 9 0.89 8 7 0.85
V 20 33 32 21
Fischer 4 26 42 40 28
Location of aneurysm
ACoA 9 14 12 11
MCA 9 9 13 5
PCoA 2 8 3 7
BA 3 4 7 0
PICA 2 3 3 2
Others 1 4 2 3
Treatment
Endovascular coiling 21 35 0.96 33 23 0.77
Surgical clipping 5 7 7 5
Yrs years, SD standard deviation, ACoA anterior communicating artery, MCA middle cerebral artery, PCoA posterior communicating artery, BA
basilar artery, PICA posterior and inferior cerebrellar artery, GOS Glasgow Outcome Scale: died (GOS1), vegetative status (GOS 2), severe
disability (GOS3), moderate disability (GOS4), good recovery (GOS5)
Table 2 Comparison of metabolic parameters between unfavorable and favorable outcome patients
Parameters Units Glasgow Outcome Scale at 12 months p value
Unfavorable (GOS 1–3) Favorable (GOS 4–5)
MR – 4.80 (4.07–5.27) 5.29 (5.05–5.76) 0.0001
LOI – 0.05 (0.03–0.1) 0.03 (0.02–0.04) <0.0001
avDO2 mmol/L 1.61 ± 0.54 1.97 ± 0.52 0.005
avDGluc mmol/L 0.35 (0.28–0.42) 0.35 (0.29–0.44) 0.837
JaDL mmol/L 0.09 (0.05–0.13) 0.05 (0.03–0.07) 0.0004
Jugular venous lactate mmol/L 1.12 (1.02–1.55) 1.02 (0.91–1.19) 0.017
Arterial lactate mmol/L 1.02 (0.91–1.37) 0.91 (0.86–1.15) 0.042
Arterial glucose mmol/L 7.25 (6.65–7.89) 7.62 (6.71–7.94) 0.533
SjVO2 % 75.4 ± 8.2 71.3 ± 6.4 0.032
PaCO2 kPa 4.9 (4.72–5.22) 4.97 (4.65–5.30) 0.808
Jugular venous pH – 7.40 ± 0.03 7.39 + 0.02 0.167
A total of 2012 biochemical events (4,024 samples) were analyzed. Averaged data are presented with the mean (±standard deviation) or median
(25th–75th percentiles)
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Predictors of the Outcome
A 2,012 results were recorded according to outcome group
(GOS 1 = 718, GOS 2 = 176, GOS 3 = 356, GOS
4 = 356, GOS 5 = 406 biochemical events). Percentages
of events of decreased MR (<3.35), increased LOI
(>0.08) and SjVO2 (B55 and C75 %) are presented
according to outcome at 12 months after aSAH (Fig. 1).
Favorable outcome was generally associated with fewer
events of decreased MR, fewer events of increased LOI,
and fewer events of increased SjVO2, in comparison with
the poor outcome. For non-survivors, about 40 and 50 % of
the biochemical events were characterized by increased
LOI and SjVO2 values, respectively, whereas more than
20 % were characterized by a decreased MR (Fig. 1). This
decreased MR in unfavorable outcome was associated with
an increased avDgluc compared with favorable outcome
[0.43 (0.33–0.63) and 0.35 (0.33–0.46), respectively,
p < 0.0001] but also with a decreased avDO2 [1.07 (0.84–
1.41) and 2.0 (1.93–2.46), respectively, p < 0.0001].
Confirming these global observations, we found that the
number of decreased MR events was significantly different
between the unfavorable and favorable outcome groups
[5 (4–8) vs. 1 (0–1.5), p < 0.0001]. The number of events
with LOI >0.08 and SjVO2 C75 % was higher in the
group with unfavorable outcome than in the group with
favorable outcome [9.5 (3–13.5) vs. 1.5 (0–3), p < 0.0001
and 14 (8.5–19) vs. 7.5 (4–12.5), p = 0.0029, respec-
tively]. Using a multiple regression analysis, we tested the
numbers of MR, LOI, SjVO2, age, and WFNS to predict
outcome. Only MR values were predictive of a poor out-
come (p < 0.0001).
Using ROC curves, we confirmed the results obtained by
multiple regression analysis: patients experiencing at least
three events of MR <3.35 were likely to have a poor
outcome whereas we did not find any cutoff value with
sensitivity and specificity higher than 80 % for the number
of LOI events (Fig. 2). Finally, the number of SjVO2 was
too unspecific to predict the outcome.
For non-survivors, we observed that the number of MR
<3.35 and LOI >0.08 events was significantly higher than
for survivors [5 (0–17) vs. 1.5 (0–19), p = 0.0009 and 10
(2–53) vs. 2 (0–46), p = 0.0001, respectively]. However,
no difference was seen between these two groups regarding
the number of SjVO2 B55 % and SjVO2 C75 % events
(p = 0.55 and p = 0.30, respectively).
MR and Lactate
Abnormal brain lactate production (JaDL greater than the
97.5th percentile of normal for awake humans, i.e.,
0.20 mmol/L, Gibbs 1942) was not uncommon, occurring
in 194 of the 2,012 biochemical events we reported
(9.6 %). This phenomenon was uncommon in good out-
come patients (4 %) and more present in the unfavorable
outcome group (13 %). The jugular venous lactate and
JaDL values were higher in the group of patients with MR
<3.35 than in the group of patients with normal MR [1.15
(0.97–1.51) vs. 1.08 (0.90–1.36), p = 0.0001 and 0.1
(0.03–0.15) vs. 0.07 (0.03–0.13), p = 0.0036, respec-
tively]. In the aSAH cohort, 161 of the 2,012 JaDL values
were negative, indicating brain uptake of lactate, and 50
out of the 68 patients (74 %) had at least one episode of
brain lactate uptake. Lactate uptake events were reported
more frequently in the favorable than in the unfavorable
outcome group (11.8 vs. 6.2 %, respectively). However,
lactate uptake likely linked to RH was more frequent in the
unfavorable outcome group (26.9 vs. 8.4 %).
MR and Cerebral Vasospasm
Cerebral vasospasm was detected in 34 patients (50 %).
Nine patients were excluded due to early vasospasm before
the jugular catheter was inserted. Among the 25 remaining
patients, the outcome was favorable in 10 patients whereas
it was unfavorable in the 15 other patients.
Near the detection time of the cerebral vasospasm, the
MR was significantly decreased in comparison to the pre-
vious sample collected 8 h earlier [3.60 (3.09–4.81) vs.
5.76 (4.49–8.99), respectively, p = 0.0001]. After diag-
nosis and treatment of cerebral vasospasm, the MR
generally increased, returning to initial values, although the
values could be divided into two classes (low MR and
Table 3 Designing cutoff values
Parameters median
(25th–75th percentile)
Glasgow Outcome Scale at 12 months
Unfavorable (GOS 1–3) Favorable (GOS 4–5) p value Cutoff Se Sp AUC
MR min 2.96 (2.28–3.29) 3.90 (3.49–4.30) <0.0001 <3.35 82.50 82.14 0.858
LOI max 0.13 (0.09–0.30) 0.07 (0.06–0.09) <0.0001 >0.08 80 70 0.821
SjVO2 min 0.648 (0.585–0.698) 0.616 (0.562–0.648) 0.06 Not found – – 0.633
SjVO2 max 0.853 (0.802 –0.903) 0.801 (0.770–0.826) 0.0004 Not found – – 0.733
Se sensitivity, Sp specificity, AUC area under the ROC curve
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normal MR) 32 h after cerebral vasospasm diagnosis and
treatment as indicated by box plots in Fig. 3a–c.
In the favorable outcome group, the decrease in the MR
at the detection time of cerebral vasospasm was reported
with a median statistically lower in comparison with
baseline values [3.94 (3.26–5.36) vs. 5.90 (4.53–6.69),
respectively, p = 0.004]. However, this decrease was not
found in the following samples (Fig. 3a). In the unfavor-
able outcome group, the decrease in the MR was clearly
shown with a median statistically lower at the time of
detection of cerebral vasospasm in comparison with base-
line values [3.60 (2.54–4.70) vs. 5.72 (4.57–9.66),
respectively, p = 0.001]. Moreover, this decrease
remained significant 8 h after the detection and treatment
of cerebral vasospasm, with values mostly below the cutoff
of 3.35. Finally, MR medians at following points increased
and returned to normal values. However, the values
obtained 32 h after cerebral vasospasm remained statisti-
cally lower than the baseline values (p = 0.04),
highlighting that half of patients exhibited values below the
cutoff of 3.35 (Fig. 3b). For these 15 patients, cerebral
infarction was detected in all patients after cerebral vaso-
spasm detection and death occurred in eight patients. Based
only on the eight patients who died, the MR tended to be
more decreased 8 h after cerebral vasospasm detection and
treatment (Fig. 3c).
Discussion
Summary of Findings
Among the advantages provided by this study, it is worth to
mention the clinical homogeneity of our poor-grade aSAH
Fig. 1 Percentage of events with MR <3.35 (a), with LOI >0.08
(b), with SjVO2 B55 and C75 % (c, d) according to outcome at
12 months. The percentage of events with metabolic ratio
(MR < 3.35, a), lactate oxygen index (LOI > 0.08, b), and jugular
venous saturation of oxygen [SjVO2 (B55 and C75 %), c, d] is shown
according to the Glasgow Outcome Scale at 12 months after aSAH.
Overall, there was a decrease in the frequency of biochemical events
with low MR and high LOI from unfavorable (GOS 1–3) to favorable
(GOS 4–5) outcome. In patients with full recovery, the frequency of
biochemical events with low MR is less than 5 %. Whereas the
frequency of elevated SjVO2 was high in our cohort, the frequency of
low SjVO2 was inferior to 10 %. In unfavorable outcome, we found
lower SjVO2 B55 % and higher SjVO2 C75 % than in favorable
outcome. Glasgow Outcome Scale: died (GOS 1), vegetative status
(GOS 2), severe disability (GOS 3), moderate disability (GOS 4),
good recovery (GOS 5)
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cohort, the high number of patients (n = 68) and of cor-
responding biochemical events (n = 2,012) recorded.
Reproducible analysis of glucose measurement enabled the
MR to be assessed and proposed as a marker of cerebral
metabolism in aSAH patients for whom jugular and arterial
samples were obtained. The major finding was that a
decrease in the MR is predictive of a poor outcome in poor-
grade aSAH patients. The frequency of MR decrease
events was significantly associated with an unfavorable
outcome. Moreover, in patients who developed a cerebral
vasospasm, the MR decreased concomitantly with the
development of vasospasm and lasted longer in patients
with more severe outcomes.
Characteristics of the Population
In poor-grade SAH patients, many factors are likely to
contribute to severe brain injury such as global cerebral
edema, vasospasm, and cortical spreading depolarization.
These conditions are known to increase the risk of mor-
tality and to worsen the long-term functional outcome [18,
19]. In our study, 41 % of the patients achieved a favorable
outcome at 12 months (GOS 4–5), while 38 % died and
21 % survived in a vegetative state or with a severe dis-
ability. Overall, these data are similar to those obtained in
larger studies performed to predict the outcome at
discharge in poor-grade aSAH patients. In a recent North-
American study, in which a subgroup of 288 poor-grade
(Hunt and Hess IV-V) aSAH patients was used, 36.8 %
achieved a good outcome (GOS 4–5) and 40.9 % died [20].
However, the authors highlighted a limit of their study
since the outcome could be measured at the first post-dis-
charge clinical appointment (follow-up between 30 and
120 days post-SAH) or upon discharge when post-dis-
charge follow-up was not available [21]. In our study,
patients without assessment at 12 months were systemati-
cally excluded. In a recent Japanese study, 34 % of the 283
poor-grade (WFNS IV–V) aSAH patients included
achieved a favorable outcome at discharge, whereas the
mortality rate was only 23.7 % [22].
Oxygen, Glucose, and Lactate Metabolism
After aSAH, secondary oxidative stress causes mitochon-
drial damage and a dysfunction of oxidative
phosphorylation leading to anaerobic glycolysis and aci-
dosis [23]. Impairment of oxidative metabolism can lead or
be linked to an increase in cerebral glycolysis for ATP
synthesis.
It is known that lactate brain concentrations are modified
in case of brain injury [24]. In the past, it was generally
admitted that lactate rose in the jugular vein in response to
ischemic insults [25]. This contributed to the use of LOI
and JaDL as markers of ischemic insult, reflecting anaer-
obic lactate metabolism. However, more recent studies
suggested that activated astrocytes modify lactate transport
and its release into the blood [26]. It is now generally
accepted that, in the brain, lactate is transported across
cellular membranes by diffusion and also mediated by
mono carboxylic acid transporters [27]. Lactate brain
transfer is therefore conditioned by several factors,
including its metabolism and the kinetics of its transporters
[28–30]. According to the results of this study, it is inter-
esting to note that we found a statistical increase in jugular
venous lactate, LOI and/or JaDL in unfavorable outcome
patients, with a high brain lactate release (JaDL > 0.2)
found in 13 % of the total measurements. This high brain
lactate release was found in 31 out of the 40 unfavorable
outcome patients. However, it is difficult to claim that an
increase in jugular venous lactate is always related to
pathological accumulation of lactate, as we detected high
levels of JaDL in 4 % of the total measurements and in 11
out of the 28 favorable outcome patients. Lactate increases
in the jugular vein are difficult to interpret without mea-
suring cerebral blood flow which provides the right
cerebral metabolic rate of lactate (CMRlac) measurement.
The lactate level in the jugular vein may be linked to
oxygenation and perfusion disorder or related to disorder of
its clearance. As previously reported by Oertel et al. [11],
Fig. 2 ROC curves of numbers of metabolic ratio (Nb MR < 3.35),
lactate oxygen index (Nb LOI > 0.08), and jugular venous saturation
of oxygen (Nb SjVO2 B55 and C75 %). Patients experiencing at least
three events of MR <3.35 were likely to have a poor outcome, the
sensitivity, the specificity, and the area under the curve being at 90,
82.1, and 0.88 %, respectively. None of the others biomarkers reach
enough sensitivity and specificity up to 80 %. ROC receiver operating
characteristic
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an increase in venous lactate was more frequent in RH
events. Moreover, in our study, JaDL was also found fre-
quently increased in studies with RH. As these repeated
episodes of RH were associated with poor outcome, the
concomitant presence of RH and increase in jugular lactate
suggests a pathological situation where brain becomes
unable to use cerebral lactate as a fuel. When metabolic
crisis occurs, it has been shown that glycogen can be
converted into lactate and that astrocytic transporters may
easily react to this increased lactate flow to provide fuel
[31]. In our study, brain lactate uptake occurred statistically
more often in favorable than in unfavorable outcome
patients (11 vs. 6.2 %) indicating that this source of lactate
was efficiently used by the brain to compensate energy
failure. Interestingly, Glenn et al. developed a theory with
two different scenarios of brain lactate uptake after trau-
matic brain injury (TBI): in a favorable outcome scenario,
uptake of lactate by the brain occurs by facilitated transport
from blood in patients with less depressed cerebral meta-
bolic rate of oxygen (CRMO2), and lactate is finally used
as a fuel. In an unfavorable outcome scenario, large
amounts of arterial lactate enter passively through a dam-
aged blood–brain barrier in patients who have severely
depressed CMRO2 [10]. In our study, in an unfavorable
outcome scenario, lactate uptake was more often associated
with RH and decrease in the avDO2. In the favorable
outcome scenario, whereas brain lactate uptake was more
frequent, it was rarely associated with RH events.
More recently, a study using microdialysis in 31 SAH
patients showed an elevation of brain extracellular lactate
more often associated with cerebral hyperglycolysis than
with brain hypoxia [32]. In this study, the increase in
extracellular lactate was more often associated with
hyperglycolysis in patients with better long-term recovery,
whereas this lactate increase was more often associated
with hypoxia in patients who died. Lactate secondary to
Fig. 3 MR values and cerebral vasospasm (CV) in favorable
outcome (a), unfavorable outcome (b), and dead patients (c). MR
values were represented before, during, and after detection and
treatment of CV, in the favorable outcome group (a), in the
unfavorable outcome group (b), and in died patients (c). Overall,
MR is significantly decreased during the CV. In unfavorable (GOS
1–3) and in died patients, the decrease is more pronounced in the time
than in favorable outcome (GOS 4–5). BCV before CV, T0CV time of
diagnostic and treatment of CV, T1CV T0CV + 8 h, T2CV
T0CV + 16 h, T3CV T0CV + 24 h, T4CV T0CV + 32 h, GOS
Glasgow Outcome Scale
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aerobic metabolism would be used to supply energy needs
of neurons whereas the lactate secondary to anaerobic
metabolism would be the result of cell energy failure and
neuronal loss. Cerebral glucose metabolism was investi-
gated by two different methods: our approach was general
and used the differences between arterial and jugular
metabolites, whereas their approach was local and used
extracellular brain lactate, pyruvate, and cerebral oxygen.
Clearly, a comparative study of aSAH combining these two
approaches would be of great interest since they seem to be
complementary.
Biomarkers as Predictors of Outcome
Our work confirms previous studies in TBI patients which
demonstrated the prognostic importance of acute damage
in cerebral oxidative metabolism and how its interaction
with glycolysis impacts the long-term outcome [10, 33].
Analyzing data obtained from a large number of repe-
ated measurements performed in individuals is problematic
from a statistical point of view. To predict the outcome, we
chose to calculate the number of events of pathophysio-
logical phenomenon which can occur at multiple times in a
patient, such as LOI and MR. Prior to calculate the number
of events, we needed to define the cutoff value for each
parameter using ROC curves. A RH was defined as a MR
<3.35. This cutoff value for MR (<3.35) was found
slightly lower than that designed by Glenn et al. [10] in a
prospective TBI study (<3.44), which was further used by
Oertel et al. [11] in SAH patients. With our cutoff value,
we increased the specificity from 75 to 82.1 % compared
with a value of 3.44. This can be explained by the fact that
our studied population was different from that of Glenn
et al. These authors defined the cutoff of RH using the
value below the 2.5th percentile of a normal cohort con-
stituted of 30 healthy volunteer subjects. The cutoff value
obtained for LOI (>0.08) in our study was identical to the
value previously reported in patients who developed cere-
bral infarction [23, 34]. Since we did not obtain any value
able to give an AUC C0.800 for SjVO2, we decided to use
the extreme values given by White et al. (55 and 75 %)
[35].
We identified at least one event of RH in 83 % of
patients and more frequently in unfavorable outcome
patients. These events were generally related to both
avDO2 decrease and avDgluc increase. However, as avDO2
and avDgluc did not predict accurately the outcome, the
use of the MR preferentially to avDO2 or avDgluc alone
was justified. A number of three or more RH events during
the monitoring of the patient was highly specific and sen-
sitive to predict the outcome, confirming the data obtained
by Oertel et al. [11], who suggested that MR values are
probably predictive of outcome in a study of 21 different
grades in SAH patients.
In this study, as for glucose, the disturbances in lactate
concentrations and ratios using lactate were different
depending on the outcomes. However, if a statistically
significant difference was found in lactate concentrations
between poor and favorable outcomes, the number of
pathological LOI events did not reach enough sensitivity
and specificity, to be considered an reliable biomarker. The
LOI is dependent on the JaDL and avDO2 values. The
clinical use of the LOI and/or JaDL using jugular bulb
catheters remains debated since its interest was shown in
ischemic injury in comatose TBI patients [36], with etiol-
ogies such as aSAH or cardiovascular disease [25, 37, 38],
whereas others studies concluded that the JaDL values did
not correlate with increased cerebral lactate concentration
measured by cerebral microdialysis [39].
MR and Vasospasm
Early brain injury and vasospasm are likely to be the major
causes of death and disability in SAH [40]. In our cohort,
the MR was clearly decreased when the vasospasm
occurred. We observed that this decrease could be
explained by several mechanisms: (1) In some cases, a
large increase in avDgluc was associated with a smaller
increase in avDO2 (decrease in SjVO2), representing an
increase in cerebral glucose and oxygen extraction during
cerebral vasospasm. However, other factors could increase
cerebral metabolic demand such as seizures or pyrexia. (2)
In other cases, the MR decrease was associated with a large
decrease in avDO2 (increase in SjVO2). This suggested that
brain tissue was unable to extract oxygen from the blood or
that a vascular shunt was present, leading to ischemic
injury. It was reported that SjVO2 decrease may be fre-
quently associated with hyperemia [35]. Independently,
several studies reported that low SjVO2 and high SjVO2
were associated with poorer outcomes after severe head
injury [34, 41]. In our population of poor-grade aSAH
patients with cerebral vasospasm, the kinetic of MR values
was different between the unfavorable and the favorable
outcomes. Whereas the MR remained normal for 32 h after
the detection of cerebral vasospasm in patients with good
recovery, it seems that the MR was decreased for a longer
period in unfavorable outcome patients. This point could be
used in prospective studies to confirm the occurrence of
vasospasm.
Study Limitations
Our study has several limitations: (1) The general mea-
surements that we obtained by jugular venous
242 Neurocrit Care (2013) 18:234–244
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catheterization may not adequately reflect regional meta-
bolic differences. (2) Measurements were obtained
discontinuously every 8 h, which is a limit for parameters
with rapid kinetic. (3) Although this single-center cohort is
the most important cohort reported which uses catheter
jugular biomarkers in poor-grade aSAH patients, other
centers should confirm our data before validating them in a
prospective cohort and finally proposing this use of the MR
as a routine test. (4) Without a direct measurement of
cerebral blood flow (i.e., by functional imaging), cerebral
metabolism should be cautiously interpreted.
Conclusion
This study confirms the interest of the MR in cerebral
glucose metabolism monitoring, especially in poor-grade
SAH patients in whom neurological deterioration may
happen unrecognized. The MR was shown as a predictor of
outcome in poor-grade aSAH patients at 12 months. Poor-
grade SAH patients required different monitoring tech-
niques to identify secondary brain insults. Interventional
prospective studies should be designed to verify its clinical
utility in guiding therapy and its value in early detection of
secondary brain injuries that are still potentially reversible,
including vasospasm.
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